Impact of high-throughput screening in biomedical research
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry. Moreover, it has been blamed for stifling the creativity that drug discovery demands. In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cell-based phenotypic screening of chemical libraries represents a powerful tool to identify new potential drugs48.”
From Identification and characterization of Cardiac Glycosides as senolytic compounds (2019) · cites this paper as [48]
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“HTS laboratories have pioneered and implemented rigorous quality assurance methods, such as Z′ trend monitoring”
MethodCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“These efforts typically take 2–3 years in most drug discovery companie”
BackgroundDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · cited 1×
“There have been numerous analyses of pharmaceutical industry productivity, and several of these have blamed high-throughput screening (HTS) as a factor undermining the creativity that has sustained the industry over the past centur”
BackgroundDiscovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Hit and lead generation: beyond high-throughput screening
Bleicher, K. H., Böhm, H.-J., Müller, K., & Alanine, A. I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1086 · Cited by 1,056
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939 · cited 1×
“This approach was used to discover compounds that inhibited hepatitis C virus replication and, after consequent optimization, the approach yielded efficacious clinical candidates with a broad genotype coverag”
MethodA Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Research works printed but not linked: 5
- Landers, P. Human Element: drug industry's big push into technology falls short — testing machines were built to streamline research — but may be stifling it — officials see payoff after 2010. The Wall Street Journal 1 (24 Feb 2004).
- Mullin, R. As high-throughput screening draws fire, researchers leverage science to put automation into perspective. Chem. Eng. News 82, 23–32 (2004).
- HTStec Limited. Cellular Assay Reagents Trends 2009 Report (Cambridge, UK, 2009).
- LaMattina, J. L. (ed.) in Drug Truths: Dispelling the Myths About Pharma R&D 65–66 (John Wiley and Sons, Inc., Hoboken, New Jersey, 2009).
- Inglese, J. in Ask the Expert Forum, ACS Chemical Biology. ACS Publications [online] http://community.acs.org/ChemBiol/AsktheExpert/AsktheExpertArchive/tabid/67/Default.aspx (2008).
Cited by
Items 101–200 of 1,000
Fabrication of active targeting lipid nanoparticles: Challenges and perspectives
Menon, I., Zaroudi, M., Zhang, Y., Aisenbrey, E. A., & Hui, L. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100299 · Cited by 144
High-Throughput Automation in Chemical Process Development
Selekman, J. A., Qiu, J. X., Tran, K., Stevens, J. M., Rosso, V. W., Simmons, E. M., Xiao, Y., & Janey, J. M. (2017) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-060816-101411 · Cited by 130
ChemOS 2.0: An orchestration architecture for chemical self-driving laboratories
Sim, M., Vakili, M. G., Strieth‐Kalthoff, F., Hao, H., Hickman, R. J., Miret, S., Pablo‐García, S., & Aspuru‐Guzik, A. (2024) · Matter · doi:10.1016/j.matt.2024.04.022 · Cited by 130
Integrating Human Pluripotent Stem Cells into Drug Development
Engle, S. J., & Puppala, D. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.05.011 · Cited by 137
Early State Research on Antifungal Natural Products
Negri, M., Salci, T. P., Mesquita, C. S. S., Capoci, I. R. G., Svidzinski, T. I. E., & Kioshima, É. S. (2014) · Molecules · doi:10.3390/molecules19032925 · Cited by 147
“Even with the evolution and emergence of new methodologies for HTS, these techniques are time consuming and expensive, especially when the tests are based on cellular assays [193].”
MethodPushing the Limits of High Throughput PET-RAFT Polymerization
Ng, G., Yeow, J., Chapman, R., Isahak, N., Wolvetang, E. J., Cooper-White, J. J., & Boyer, C. A. (2018) · Macromolecules · doi:10.1021/acs.macromol.8b01600 · Cited by 127
Droplet control technologies for microfluidic high throughput screening (μHTS)
Şeşen, M., Alan, T., & Neild, A. (2017) · Lab on a Chip · doi:10.1039/c7lc00005g · Cited by 133
An active role for machine learning in drug development
Murphy, R. F. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.576 · Cited by 126
Generative Network Complex for the Automated Generation of Drug-like Molecules
Gao, K., Nguyen, D. D., Tu, M., & Wei, G. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00599 · Cited by 128
Automation and machine learning augmented by large language models in a catalysis study
Su, Y., Wang, X., Ye, Y., Xie, Y., Xu, Y., Jiang, Y., & Wang, C. (2024) · Chemical Science · doi:10.1039/d3sc07012c · Cited by 107
Zheng, J., Wu, M. H., Wang, H., Li, S., Wang, X., Li, Y., Wang, D., & Li, S. (2018) · Cancers · doi:10.3390/cancers10110461 · Cited by 132
“High-throughput methods are an integral part of pharmacological studies and have led to many achievements in biomedical fields [32].”
BackgroundDynamic Combinatorial Chemistry: A New Methodology Comes of Age
Frei, P., Hevey, R., & Ernst, B. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201803365 · Cited by 135
In vitro assays and techniques utilized in anticancer drug discovery
Ediriweera, M. K., Tennekoon, K. H., & Samarakoon, S. R. (2018) · Journal of Applied Toxicology · doi:10.1002/jat.3658 · Cited by 129
“Techniques such as fluorescence resonance energy transfer and homogeneous time resolved fluorescence have been coupled with HTS to improve its output.”
BackgroundMethodInfluentialWang, Y., Lu, J., Lin, C.-C., Chin, Y., Wu, T., Lin, L., Lai, Z.-Z., Kuo, S.-C., & Ho, Y. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.10.003 · Cited by 113
“In this report, we described the use of an CHIKV 26S mediated insect cell fusion inhibition assay that uses baculovirus-based expression as a high-throughput screening (HTS) system to search for novel anti-CHIKV drugs (Macarron et al., 2011).”
MethodMapping the Efficiency and Physicochemical Trajectories of Successful Optimizations
Young, R. J., & Leeson, P. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00180 · Cited by 121
The Transcription Factor NF-κB in Stem Cells and Development
Kaltschmidt, C., Greiner, J. F. W., & Kaltschmidt, B. (2021) · Cells · doi:10.3390/cells10082042 · Cited by 115
Large language models for chemistry robotics
Yoshikawa, N., Skreta, M., Darvish, K., Arellano-Rubach, S., Ji, Z., Bjørn Kristensen, L., Li, A. Z., Zhao, Y., Xu, H., Kuramshin, A., et al. (2023) · Autonomous Robots · doi:10.1007/s10514-023-10136-2 · Cited by 112
“Once the program has been verified, it is passed on to a task and motion planner (TAMP) for execution by a robot. executed by the robot, requiring task-plan verification (Garrett et al., 2020; Ahn et al., 2022).”
MethodAdvancing pharmaceutical research: A comprehensive review of cutting-edge tools and technologies
Chen, J., Lin, A., & Luo, P. (2024) · Current Pharmaceutical Analysis · doi:10.1016/j.cpan.2024.11.001 · Cited by 112
Belema, M., & Meanwell, N. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500335h · Cited by 124
Chemical Biology Probes from Advanced DNA-encoded Libraries
Salamon, H., Škopić, M. K., Jung, K., Bugain, O., & Brunschweiger, A. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00981 · Cited by 116
Hit Dexter 2.0: Machine-Learning Models for the Prediction of Frequent Hitters
Stork, C., Chen, Y., Šícho, M., & Kirchmair, J. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00677 · Cited by 110
DNA-Encoded Dynamic Chemical Library and Its Applications in Ligand Discovery
Zhou, Y., Li, C., Peng, J., Xie, L., Meng, L. H., Li, Q., Zhang, J., Li, X., Li, X., Huang, X., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b09277 · Cited by 111
Ban, F., Dalal, K., Li, H., LeBlanc, E., Rennie, P. S., & Cherkasov, A. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00137 · Cited by 109
Subbaiah, M. A. M., Rautio, J., & Meanwell, N. A. (2024) · Chemical Society Reviews · doi:10.1039/d2cs00957a · Cited by 115
Application of computational methods for anticancer drug discovery, design, and optimization
Prada‐Gracia, D., Huerta‐Yépez, S., & Moreno‐Vargas, L. M. (2016) · Boletín Médico del Hospital Infantil de México · doi:10.1016/j.bmhimx.2016.10.006 · Cited by 119
A digital microfluidic method for multiplexed cell-based apoptosis assays
Bogojevic, D., Chamberlain, M. D., Barbulovic-Nad, I., & Wheeler, A. R. (2012) · Lab Chip · doi:10.1039/c2lc20893h · Cited by 103
Cell-Based Assays in High-Throughput Screening for Drug Discovery
Yang, Wang, Zang, Tang, & Li (2012) · International Journal of Biotechnology for Wellness Industries · doi:10.6000/1927-3037.2012.01.01.02 · Cited by 138
Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update
Roskoski, R. J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107723 · Cited by 109
Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening
Manjunatha, U. H., & Smith, P. W. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.031 · Cited by 111
Analysis of pharma R&D productivity – a new perspective needed
Schuhmacher, A., Hinder, M., Stein, A. V. S. U., Hartl, D., & Gassmann, O. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103726 · Cited by 112
Heteromers of μ‐δ opioid receptors: new pharmacology and novel therapeutic possibilities
Fujita, W., Gomes, I., & Devi, L. A. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12663 · Cited by 98
“…created the Molecular Libraries Initiative and the Molecular Libraries Screening Center Network to facilitate the establish- ment of translational and chemical screening programs at academic screening centers (http://www.slas.org/screening Facilities/facilityList.cfm) (Macarron et al., 2011).”
PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens
Bush, E. C., Ray, F., Alvarez, M. J., Realubit, R., Li, H., Karan, C., Califano, A., & Sims, P. A. (2017) · Nature Communications · doi:10.1038/s41467-017-00136-z · Cited by 107
A DNA‐Encoded Chemical Library Incorporating Elements of Natural Macrocycles
Stress, C., Sauter, B., Schneider, L. A., Sharpe, T., & Gillingham, D. G. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201902513 · Cited by 100
Self-driving laboratories: A paradigm shift in nanomedicine development
Hickman, R. J., Bannigan, P., Bao, Z., Aspuru-Guzik, A., & Allen, C. (2023) · Matter · doi:10.1016/j.matt.2023.02.007 · Cited by 84
Bayesian Models Leveraging Bioactivity and Cytotoxicity Information for Drug Discovery
Ekins, S., Reynolds, R. C., Kim, H., Koo, M.-S., Ekonomidis, M., Talaue, M., Paget, S. D., Woolhiser, L. K., Lenaerts, A. J., Bunin, B. A., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.01.011 · Cited by 97
“…whole-cell high-throughput screens (HTS) of commercial libraries have searched for inhibitors of mycobacterial growth, at a cost of millions of dollars, with resultant low single-digit (or less) hit rates (Macarron et al., 2011, Magnet et al., 2010, Mak et al., 2012, Stanley et al., 2012).”
BackgroundWang, X., Zhu, H., Jiang, Y., Li, Y., Tang, C., Chen, X., Li, Y., Liu, Q., & Liu, Q. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab587 · Cited by 106
“However, it is not feasible to test the complete combination space with HTS, and it requires significant cost infrastructure construction [16].”
Mn-based cGAS-STING activation for tumor therapy
Huang, A., & Zhou, W. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.01.04 · Cited by 108
Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?
Hatzis, C., Bedard, P. L., Birkbak, N. J., Beck, A. H., Aerts, H. J. W. L., Stern, D. F., Shi, L., Clarke, R., Quackenbush, J., & Haibe-Kains, B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0725 · Cited by 99
“HTS has become one of the primary scientific tools used in the pharmaceutical industry to generate new leads (13).”
BackgroundUsing Information from Historical High-Throughput Screens to Predict Active Compounds
Riniker, S., Wang, Y., Jenkins, J. L., & Landrum, G. A. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500190p · Cited by 93
Priya, S., & Satheeshkumar, P. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818593-3.00005-1 · Cited by 96
Filtering promiscuous compounds in early drug discovery: is it a good idea?
Senger, M. R., Fraga, C. A. M., Dantas, R. F., & Silva, F. P. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.004 · Cited by 95
Ai, C., Yang, H., Liu, X., Dong, R., Ding, Y., & Guo, F. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012229 · Cited by 106
“Traditional drug design works utilize high-throughput technology [4] and conduct virtual screening [5] from existing molecules.”
BackgroundAt the Crossroads of Nanotoxicology in vitro : Past Achievements and Current Challenges
Hussain, S. M., Warheit, D. B., Ng, S. P., Comfort, K. K., Grabinski, C. M., & Braydich‐Stolle, L. K. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv106 · Cited by 115
“Examining these 2 statements together, it becomes apparent that to keep up with the pace of NM development and fully identify safety concerns, a rapid, high-throughput screening approach is needed (Macarron et al., 2011).”
BackgroundAlberga, D., Gambacorta, N., Trisciuzzi, D., Ciriaco, F., Amoroso, N., & Nicolotti, O. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00517 · Cited by 97
Identification of Small-Molecule Frequent Hitters from AlphaScreen High-Throughput Screens
Schorpp, K., Rothenaigner, I., Salmina, E. S., Reinshagen, J., Low, T., Brenke, J. K., Gopalakrishnan, J., Tetko, I. V., Gul, S., & Hadian, K. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113516861 · Cited by 92
The compromise of virtual screening and its impact on drug discovery
Slater, O., & Kontoyianni, M. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1604677 · Cited by 92
“[133] indicated that HTS success was consistently 60% in the”
BackgroundOpportunities and Challenges for Fatty Acid Mimetics in Drug Discovery
Proschak, E., Heitel, P., Kalinowsky, L., & Merk, D. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01287 · Cited by 85
Tee, W.-V., Guarnera, E., & Berezovsky, I. N. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006228 · Cited by 91
Biophysical Screening for the Discovery of Small-Molecule Ligands
Ciulli, A. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-398-5_13 · Cited by 105
Selecting, Acquiring, and Using Small Molecule Libraries for High‐Throughput Screening
Dandapani, S., Rossé, G., Southall, N. T., Salvino, J. M., & Thomas, C. J. (2012) · Current Protocols in Chemical Biology · doi:10.1002/9780470559277.ch110252 · Cited by 95
“Although there are multiple lead-generating technologies, HTS is universally used as a practical method to query large compound collections in search of novel starting points for the development of biologically active compounds (Bleicher et al., 2003; Macarron et al., 2011).”
MethodEvolution of Novartis’ Small Molecule Screening Deck Design
Schuffenhauer, A., Schneider, N., Hintermann, S., Auld, D. S., Blank, J., Cotesta, S., Engeloch, C., Fechner, N., Gaul, C., Giovannoni, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01332 · Cited by 97
Andrade, E., Bento, A. F., Cavalli, J., de Oliveira, S. K. F., Freitas, C. S., Marcon, R., Schwanke, R. C., Siqueira, J. M., & Calixto, J. Β. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165644 · Cited by 99
“It must be emphasized that all strategies of identification have strengths and weaknesses, and it is their wise combination that can lead to the most successful strategy in modern drug discovery (44).”
BackgroundEvolution of commercially available compounds for HTS
Volochnyuk, D. M., Ryabukhin, S. V., Moroz, Y. S., Savych, O., Chuprina, A., Horvath, D., Zabolotna, Y., Varnek, A. A., & Judd, D. B. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.10.016 · Cited by 84
“3, 711–716 8 Macarron, R. et al. (2011) Impact of high-throughput screening in biomedical research.”
BackgroundInfluentialChemputation and the Standardization of Chemical Informatics
Hammer, A. J. S., Leonov, A. I., Bell, N. L., & Cronin, L. (2021) · JACS Au · doi:10.1021/jacsau.1c00303 · Cited by 86
Deep scaffold hopping with multimodal transformer neural networks
Zheng, S., Lei, Z., Ai, H., Chen, H., Deng, D., & Yang, Y. (2021) · Journal of Cheminformatics · doi:10.1186/s13321-021-00565-5 · Cited by 95
“Journal of chemical information and computer sciences 1988, 28 (1), 31-36.”
BackgroundMethodInfluentialStereochemical diversity as a source of discovery in chemical biology
Scott, K. A., Ropek, N., Melillo, B. N., Schreiber, S. L., Cravatt, B. F., & Vinogradova, E. V. (2022) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2022.100028 · Cited by 87
Advancing Covalent Ligand and Drug Discovery beyond Cysteine
Kim, G., Grams, R. J., & Hsu, K. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00001 · Cited by 88
In Silico Analysis of Nanomaterials Hazard and Risk
Cohen, Y., Ralló, R., Liu, R., & Liu, H. H. (2012) · Accounts of Chemical Research · doi:10.1021/ar300049e · Cited by 95
Ma, L., Zhao, Y., Chen, Y., Cheng, B., Peng, A., & Huang, K. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.11.051 · Cited by 91
Molecular dynamics analysis to evaluate docking pose prediction
Sakano, T., Mahamood, M. I., Yamashita, T., & Fujitani, H. (2016) · Biophysics and Physicobiology · doi:10.2142/biophysico.13.0_181 · Cited by 91
Microfluidic Cell Chips for High-Throughput Drug Screening
Chi, C., Ahmed, A. H. R., Dereli‐Korkut, Z., & Wang, S. (2016) · Bioanalysis · doi:10.4155/bio-2016-0028 · Cited by 84
The rise of molecular simulations in fragment-based drug design (FBDD): an overview
Bissaro, M., Sturlese, M., & Moro, S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.06.023 · Cited by 82
“Over the past few decades, the advent of high-throughput screening (HTS) methodologies has contributed to revolutionizing the entire drug discovery process, making the identification of new candidates more efficient [1].”
Coussens, N. P., Braisted, J. C., Peryea, T., Sittampalam, G. S., Simeonov, A. M., & Hall, M. D. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.013755 · Cited by 81
“Since small-molecule screening was first implemented in the pharmaceutical industry during the early 1990s, it has proven to be a powerful methodology that enabled the development of numerous drugs, including those indicated for cancer (Table 1) (Macarron et al., 2011).”
BackgroundInfluentialSelf-citationTechniques in scaffold fabrication process for tissue engineering applications: A review
Kumar, A., & Jacob, A. (2022) · Journal of Applied Biology & Biotechnology · doi:10.7324/jabb.2022.100321 · Cited by 84
“The imaging and characterization are easier with automated lab facilities and high processing screening methodologies [16,17].”
MethodAnti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma
Wolter, J. K., Wolter, N. E., Blanch, A., Partridge, T., Cheng, L. S., Morgenstern, D. A., Podkowa, M., Kaplan, D. R., & Irwin, M. S. (2013) · Oncotarget · doi:10.18632/oncotarget.1083 · Cited by 80
Targeting receptor complexes: a new dimension in drug discovery
Ishoey, M., Clemmensen, L. S., Bredt, D. S., Bettler, B., & Strømgaard, K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0086-4 · Cited by 79
Early phase drug discovery: Cheminformatics and computational techniques in identifying lead series
Duffy, B. C., Zhu, L., Decornez, H. Y., & Kitchen, D. B. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.04.062 · Cited by 80
Mureşan, S., Petrov, P., Southan, C., Kjellberg, M. J., Kogej, T., Tyrchan, C., Varkonyi, P., & Xie, P. H. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.10.005 · Cited by 79
O’Connell, T. N., Ramsay, J., Rieth, S. F., Shapiro, M. J., & Stroh, J. G. (2014) · Analytical Chemistry · doi:10.1021/ac500938y · Cited by 78
Cruz, D. J. M., Bonotto, R. M., Gomes, R. G. B., da Silva, C. T., Taniguchi, J. B., No, J. H., Lombardot, B., Schwartz, O., Hansen, M. A. E., & Freitas-Junior, L. H. (2013) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002471 · Cited by 80
“By using high-throughput assays, a large collection of substances, from small molecules to natural products, can be evaluated for antiviral activity in a relatively short amount of time [31].”
BackgroundCellular manganese content is developmentally regulated in human dopaminergic neurons
Kumar, K. K., Lowe, Aboud, A. A., Neely, M. D., Redha, R., Bauer, J. A., Odak, M., Weaver, C. D., Meiler, J., Aschner, M., et al. (2014) · Scientific Reports · doi:10.1038/srep06801 · Cited by 78
Virtual Screening in Drug Design
Lill, M. A. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-342-8_1 · Cited by 77
Advances in G protein-coupled receptor high-throughput screening
Yasi, E. A., Kruyer, N. S., & Peralta‐Yahya, P. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.06.004 · Cited by 78
“Computational and experimental high-throughput screening (HTS) of clinically relevant GPCRs with compounds and peptides is a first-line drug discovery tool [3].”
BackgroundCompound–protein interaction prediction by deep learning: Databases, descriptors and models
Du, B.-X., Qin, Y., Jiang, Y.-F., Xu, Y., Yiu, S.-M., Yu, H., & Shi, J.-Y. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.02.023 · Cited by 73
Genome mining for the search and discovery of bioactive compounds: The Streptomyces paradigm
Ward, A., & Allenby, N. (2018) · FEMS Microbiology Letters · doi:10.1093/femsle/fny240 · Cited by 79
Changing the HTS Paradigm: AI-Driven Iterative Screening for Hit Finding
Dreiman, G. H. S., Bictash, M., Fish, P. V., Griffin, L. D., & Svensson, F. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220949495 · Cited by 87
Self-Driving Laboratories for Development of New Functional Materials and Optimizing Known Reactions
Soldatov, M. A., Butova, V. V., Pashkov, D. M., Butakova, M. A., Medvedev, P. V., Chernov, A. V., & Soldatov, A. V. (2021) · Nanomaterials · doi:10.3390/nano11030619 · Cited by 80
Kim, S., Ga, S., Bae, H., Sluyter, R., Konstantinov, K., Shrestha, L. K., Kim, Y. H., Kim, J. H., & Ariga, K. (2023) · EES Catalysis · doi:10.1039/d3ey00239j · Cited by 81
Virtual Screening Strategies in Medicinal Chemistry: The State of the Art and Current Challenges
Braga, R. C., Alves, V. M., Silva, A. C., do Nascimento, M. N., Silva, F. M., Lião, L. M., & Andrade, C. H. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666140929120749 · Cited by 84
A unified lead-oriented synthesis of over fifty molecular scaffolds
Doveston, R. G., Tosatti, P., Dow, M., Foley, D. J., Li, H. Y., Campbell, A. J., House, D., Churcher, I., Marsden, S. P., & Nelson, A. S. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob02287d · Cited by 74
Using Physicochemical Measurements to Influence Better Compound Design
Bunally, S. B., Luscombe, C. N., & Young, R. J. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219859845 · Cited by 78
An overview of DNA-encoded libraries: A versatile tool for drug discovery.
Madsen, D. H., Azevedo, C. M. G., Micco, I., Petersen, L., & Hansen, N. (2020) · Progress in Medicinal Chemistry · doi:10.1016/bs.pmch.2020.03.001 · Cited by 39
Natural products and drug discovery: a survey of stakeholders in industry and academia
Amirkia, V., & Heinrich, M. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00237 · Cited by 79
“Additionally, large HTS screening programmes are argued by many (Macarron et al., 2011) to be more cost-effective in the long run which is also in line with the third largest barrier cited by our industry contacts (i.e., cost/funding/budget).”
BackgroundBordeenithikasem, P., Liu, J., Kube, S. A., Li, Y., Ma, T., Scanley, B. E., Broadbridge, C. C., Vlassak, J. J., Singer, J. P., & Schroers, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-07719-2 · Cited by 73
DNA-encoded libraries – an efficient small molecule discovery technology for the biomedical sciences
Kunig, V. B. K., Potowski, M., Gohla, A., & Brunschweiger, A. (2018) · Biological Chemistry · doi:10.1515/hsz-2018-0119 · Cited by 74
CLOOME: contrastive learning unlocks bioimaging databases for queries with chemical structures
Sanchez-Fernandez, A., Rumetshofer, E., Hochreiter, S., & Klambauer, G. (2023) · Nature Communications · doi:10.1038/s41467-023-42328-w · Cited by 103
“In drug discovery, the effect of 319 the limited availability of data on molecules is even more severe, since the acquisition of a single bioactivity 320 data point can cost several thousand dollars and take several weeks or months [66, 67].”
BackgroundEnd-to-end automated microfluidic platform for synthetic biology: from design to functional analysis
Linshiz, G., Jensen, E. C., Stawski, N., Bi, C., Elsbree, N., Jiao, H., Kim, J., Mathies, R. A., Keasling, J. D., & Hillson, N. J. (2016) · Journal of Biological Engineering · doi:10.1186/s13036-016-0024-5 · Cited by 72
“Furthermore, the high-throughput generation of reliable and reproducible experimental data is still challenging and requires extensive laboratory automation [3, 4].”
Current versus future reproduction and longevity: a re-evaluation of predictions and mechanisms
Zhang, Y., & Hood, W. R. (2016) · Journal of Experimental Biology · doi:10.1242/jeb.132183 · Cited by 74
“High-throughput screening, next-generation sequencing and pathway analysis could reveal physiological differences between and within species (Macarron et al., 2011; Khatri et al., 2012), as well as highlighting genetic correlates with life-history patterns, which undoubtedly play an important role…”
High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model
Conant, G., Lai, B. F. L., Lu, R. X. Z., Korolj, A., Wang, E. Y., & Radisic, M. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-017-9736-2 · Cited by 75
Maier, W. F. (2019) · ACS Combinatorial Science · doi:10.1021/acscombsci.8b00189 · Cited by 70
Advances and applications in single-cell and spatial genomics
Wang, J., Ye, F., Chai, H., Jiang, Y., Wang, T., Ran, X., Xia, Q., Xu, Z., Fu, Y., Zhang, G., et al. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2770-x · Cited by 79
Wildey, M. J., Haunsø, A., Tudor, M., Webb, M. L., & Connick, J. H. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.08.004 · Cited by 92
Damiani, E., Solorio, J. A., Doyle, A. P., & WALLACE, H. M. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.12.004 · Cited by 76
High-Throughput Routes to Biomaterials Discovery
Soheilmoghaddam, M., Rumble, M., & Cooper-White, J. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01026 · Cited by 72
Ryoo, H., Kimmel, H., Rondo, E., & Underhill, G. H. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10627 · Cited by 75
“247 Furthermore, as mentioned previously, increasing regulation on animal testing and the appreciation for human-specific disease phenotypes and drug responses, have made the development of medically relevant in vitro models for drug screening imperative.”
BackgroundKogej, T., Blomberg, N., Greasley, P. J., Mundt, S. M., Vainio, M. J., Schamberger, J., Schmidt, G. P., & Hüser, J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.011 · Cited by 68
Reutlinger, M., Rodrigues, T., Schneider, P., & Schneider, G. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201307786 · Cited by 68
Si, T., Li, B., Comi, T. J., Wu, Y., Hu, P., Wu, Y., Min, Y., Mitchell, D. A., Zhao, H., & Sweedler, J. V. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b04641 · Cited by 70
DNA Encoded Libraries: A Visitor's Guide
Flood, D. T., Kingston, C., Vantourout, J. C., Dawson, P. E., & Baran, P. S. (2020) · Israel Journal of Chemistry · doi:10.1002/ijch.201900133 · Cited by 68
Phenylalanine Hydroxylase Misfolding and Pharmacological Chaperones
Underhaug, J., Aubi, O., & Martínez, A. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611212220008 · Cited by 74
Metadata
- Authors
- Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., Schopfer, U., & Sittampalam, G. S.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Novartis (United States) (US)
- Abbott (United States) (US)
- Sanofi (France) (FR)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- University of North Carolina at Chapel Hill (US)
- The University of Kansas Cancer Center (US)
- Novartis (Switzerland) (CH)
- Pfizer (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 188-195
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2031441006
- Cited by
- 1,364
- References
- 65
- Citations by year
- 2026: 113 · 2025: 117 · 2024: 99 · 2023: 103 · 2022: 82 · 2021: 107 · 2020: 106 · 2019: 77 · 2018: 105 · 2017: 87 · 2016: 96 · 2015: 64 · 2014: 61 · 2013: 73 · 2012: 54
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- high-throughput screening, drug discovery, chemical biology
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Drug Design, Biomedical Research, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.